Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Treating large B-cell lymphoma: Current strategies and unmet needs across community and academic settings.

Blood reviews·2026

Same author

Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns.

Haematologica·2026

Same author

Hodgkin Lymphoma: Introduction and History.

Cancer journal (Sudbury, Mass.)·2026

Same author

Patient-Reported Observance of a Mediterranean Diet and Physical Activity in Patients Living with Breast Cancer: Implications for Primary Care Providers.

Journal of primary care & community health·2025

Same author

CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting.

Transplantation and cellular therapy·2025

Same author

Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma.

Nature communications·2025

Search research articles

Related Experiment Video

Updated: Sep 7, 2025

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

Relapsed or Refractory Diffuse Large B-Cell Lymphoma: "Dazed and Confused".

Meghana Kesireddy, Matthew Lunning

Oncology (Williston Park, N.Y.)

|June 20, 2022

Summary

Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) treatment is evolving. New therapies like CAR-T cells and targeted agents offer hope, but optimal sequencing is crucial for patient outcomes.

Area of Science:

Hematology
Oncology
Immunotherapy

Background:

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma.
30-40% of DLBCL patients develop relapsed/refractory (R/R) disease, facing significant mortality.
Current standard for transplant-eligible R/R DLBCL is salvage chemoimmunotherapy with high-dose chemotherapy and autologous stem cell rescue (HDT-ASCR).

Purpose of the Study:

To review recent advances in R/R DLBCL management.
To discuss chimeric antigen receptor T-cell (CAR-T) therapy, targeted agents, and their sequencing.
To highlight the need for individualized treatment strategies in R/R DLBCL.

Main Methods:

Review of approved CAR-T constructs, efficacy, and adverse effects.
Analysis of bridging therapy to CAR-T.

More Related Videos

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

Related Experiment Videos

Last Updated: Sep 7, 2025

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

Evaluation of emerging targeted agents, including bispecific antibodies, and their timing relative to CAR-T therapy.

Main Results:

CAR-T therapy and targeted agents are transforming R/R DLBCL treatment landscape.
Real-world data on CAR-T efficacy and safety are emerging.
Optimal sequencing of these novel therapies remains an unmet need.

Conclusions:

Individualized treatment with careful sequencing of CAR-T and targeted agents is essential for R/R DLBCL.
Further prospective randomized clinical trials are needed to guide optimal treatment strategies.
Advances in immunotherapy and targeted therapy offer new hope for R/R DLBCL patients.